Trinity Biotech (TRIB) Restructuring Costs (2021 - 2024)

Trinity Biotech (TRIB) has reported Restructuring Costs for 4 consecutive years, with -$962000.0 the latest figure, recorded in Q4 2024.

• Quarterly Restructuring Costs fell 231.72% year-over-year to -$962000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$1.7 million (up 87.99% YoY) and the FY2024 annual result came in at -$1.4 million, up 87.32% from the prior year.
• Restructuring Costs declined to -$962000.0 in Q4 2024 per TRIB's latest filing, from -$446000.0 in the prior quarter.
• Over the last five years, Restructuring Costs for TRIB reached as high as -$290000.0 in Q4 2023 and fell as low as -$10.8 million in Q2 2023.
• A 4-year average of -$2.8 million and a median of -$962000.0 in 2024 frame the typical range for Restructuring Costs.
• Annual changes were most pronounced in 2023 — Restructuring Costs slumped 1983.82% — and 2024, when it jumped 95.88%.
• Year by year, Restructuring Costs stood at -$876000.0 in 2021, then plunged by 246.12% to -$3.0 million in 2022, then jumped by 90.44% to -$290000.0 in 2023, then slumped by 231.72% to -$962000.0 in 2024.
• According to Business Quant data, Restructuring Costs over the past three periods registered -$962000.0, -$446000.0, and -$290000.0 for Q4 2024, Q2 2024, and Q4 2023 respectively.